Acta Biomaterialia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Nature Communications, Год журнала: 2023, Номер 14(1)
Опубликована: Март 25, 2023
Abstract Nanomedicine holds great promise to enhance cancer therapy. However, low active pharmaceutical ingredient (API) loading content, unpredictable drug release, and potential toxicity from excipients limit their translational capability. We herein report a full-API nanodrug composed of FDA-approved 5-aminolevulinic acid (ALA), human essential element Fe 3+ , natural bioactive compound curcumin with an ideal API content pH-responsive release profile for continuous spatiotemporal therapy achieved by multi-step tandem endogenous biosynthesis. First, ALA enzymatically converts into photosensitizer protoporphyrin IX (PpIX). Afterward, multiple downstream products including carbon monoxide (CO), 2+ biliverdin (BV), bilirubin (BR) are individually biosynthesized through the PpIX-heme-CO/Fe /BV-BR metabolic pathway, further cooperating released curcumin, ultimately eliciting mitochondria damage, membrane disruption, intracytoplasmic injury. This work not only provides paradigm exploiting diversified metabolites tumor suppression, but also presents safe efficient nanodrug, facilitating practical translation nanodrugs.
Язык: Английский
Процитировано
56
Journal of Nanobiotechnology, Год журнала: 2023, Номер 21(1)
Опубликована: Ноя. 6, 2023
Pancreatic cancer is a highly aggressive malignancy with limited treatment options and poor prognosis. Trophoblast cell surface antigen 2 (TROP2), overexpressed in the tumors of more than half pancreatic patients, has been identified as potential target for antibody-drug conjugates (ADCs). Almost all reported TROP2-targeted ADCs are IgG type have poorly studied cancer. Here, we aimed to develop novel nanobody-drug conjugate (NDC) targeting TROP2 cancer.In this study, developed NDC, HuNbTROP2-HSA-MMAE, TROP2-positive HuNbTROP2-HSA-MMAE characterized by use nanobodies against human serum albumin (HSA) drug-antibody ratio 1. exhibited specific binding was internalized into tumor cells high endocytosis efficiency within 5 h, followed intracellular translocation lysosomes release MMAE induce apoptosis through caspase-3/9 pathway. In xenograft model cancer, doses 0.2 mg/kg 1 demonstrated significant antitumor effects, dose even eradicated tumor.HuNbTROP2-HSA-MMAE desirable affinity, internalization activity. It holds promise therapeutic option
Язык: Английский
Процитировано
53
Exploration, Год журнала: 2022, Номер 2(4)
Опубликована: Июнь 4, 2022
Self-assembled prodrug nanoparticles with tumor-responsive capacity have great potential in tumor visualization and treatment. However, the nanoparticle formulas usually contain multiple components, especially polymeric materials, which result various issues. Herein, we report an indocyanine green (ICG)-driven assembly of paclitaxel prodrugs integrating near-infrared fluorescence imaging tumor-specific chemotherapy. By feat hydrophilic merit ICG, dimer could form more uniformly monodispersed nanoparticles. This two-in-one strategy reinforces complementary advantages, resulting superior behavior, robust colloidal stability, enhanced accumulation as well desirable vivo feedback The experiments validated activation at sites evidenced by intensity, potent growth suppression, reduced systemic toxicity compared commercial Taxol. universality ICG potentiated toward photosensitizers dyes was confirmed. presentation provides deep insight into feasibility constructing clinical-close alternatives for improving antitumor efficacy.
Язык: Английский
Процитировано
56
Nano Today, Год журнала: 2023, Номер 53, С. 102030 - 102030
Опубликована: Окт. 21, 2023
Язык: Английский
Процитировано
24
Exploration, Год журнала: 2024, Номер 4(4)
Опубликована: Фев. 9, 2024
Abstract Prodrug‐based self‐assembled nanoparticles (PSNs) with tailored responses to tumor microenvironments show a significant promise for chemodynamic therapy (CDT) by generating highly toxic reactive oxygen species (ROS). However, the insufficient level of intracellular ROS and limited drug accumulation remain major challenges further clinical transformation. In this study, PSNs delivery artesunate (ARS) are demonstrated designing pH‐responsive ARS‐4‐hydroxybenzoyl hydrazide (HBZ)‐5‐amino levulinic acid (ALA) (AHA NPs) self‐supplied excellent chemotherapy CDT. The greatly improved loading capacity generation from endoperoxide bridge using electron withdrawing group attached directly C10 site artesunate. ALA ARS‐HBZ could be released AHA NPs under cleavage hydrazone bonds triggered acidic surroundings. Besides, increased heme in mitochondria, promoting lipid peroxidation anti‐tumor effects. Our study ARS through chemical modification, pointing out potential applications fields.
Язык: Английский
Процитировано
14
International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 1867 - 1886
Опубликована: Фев. 1, 2024
Abstract: Although the frequency of bone metastases from breast cancer has increased, effective treatment is lacking, prompting development nanomedicine, which involves use nanotechnology for disease diagnosis and treatment. Nanocarrier drug delivery systems offer several advantages over traditional methods, such as higher reliability biological activity, improved penetration retention, precise targeting delivery. Various nanoparticles that can selectively target tumor cells without causing harm to healthy or organs have been synthesized. Recent advances in enabled prevention metastatic diseases well ability deliver complex molecular "cargo" particles regions. Nanoparticles modulate systemic biodistribution enable targeted accumulation therapeutic agents. Several strategies are used treat metastases, including untargeted delivery, bone-targeted cell-targeted Combining agents with enhances selective payloads lesions, providing multiple In this review, we describe recent nanoparticle treating metastases. Keywords: cancer, metastasis, nanoparticle,
Язык: Английский
Процитировано
13
Advanced Functional Materials, Год журнала: 2024, Номер 34(30)
Опубликована: Март 21, 2024
Abstract The combination of chemotherapy and immunotherapy holds great potential in clinical treatment advanced cancers. Whereas, the therapeutic outcome chemotherapeutic immune regulator is suboptimal due to their poor tumor availability severe off‐target toxicity. Herein, self‐carrier nanoparticles (PSMT NPs) integrating a paclitaxel (PTX) prodrug indoleamine 2,3‐dioxygenase 1 (IDO) inhibitor (1‐methyl‐tryptophan, 1MT) for tumor‐specific chemo‐immunotherapy constructed. After internalization by cancer cells, PSMT NPs can respond endogenous redox stimulus, release PTX 1MT. released not only promote cell apoptosis via intervention mitosis but also initiate immunogenic death facilitate recruitment activation tumor‐infiltrating cytotoxic T lymphocytes. concomitant 1MT inhibit IDO activity exhaust regulatory thereby synergistically activating exhibit potentiated antitumor output toward triple‐negative breast negligible systemic This facile versatile nanoplatform provides promising strategy cooperatively activate immunity chemo‐immunotherapy.
Язык: Английский
Процитировано
12
ACS Applied Bio Materials, Год журнала: 2024, Номер 7(8), С. 5121 - 5135
Опубликована: Июль 23, 2024
Indocyanine green J-aggregates (ICG-Jagg) have emerged as a significant subject of interest in biomedical applications due to their unique optical properties, tunable size, and excellent biocompatibility. This comprehensive review aims provide an in-depth exploration ICG-Jagg, with focus on elucidating the diverse facets preparation factors that influence process. Additionally, discusses diagnostics, such imaging contrast agents, well utilization drug delivery various phototherapeutic interventions.
Язык: Английский
Процитировано
11
Chemical Engineering Journal, Год журнала: 2022, Номер 452, С. 139108 - 139108
Опубликована: Сен. 8, 2022
Язык: Английский
Процитировано
29
Acta Biomaterialia, Год журнала: 2023, Номер 164, С. 407 - 421
Опубликована: Апрель 23, 2023
Язык: Английский
Процитировано
20